The structure of human CD23 and its interactions with IgE and CD21 by Hibbert, RG et al.
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
 
JEM © The Rockefeller University Press $8.00
Vol. 202, No. 6, September 19, 2005 751–760 www.jem.org/cgi/doi/10.1084/jem.20050811
 
ARTICLE
 
751
The structure of human CD23 and its 
interactions with IgE and CD21
 
Richard G. Hibbert,
 
1
 
 Peter Teriete,
 
1
 
 Gabrielle J. Grundy,
 
2
 
 Rebecca L. Beavil,
 
2
 
 
Rajko Reljic´,
 
2 
 
V. Michael Holers,
 
3,4
 
 Jonathan P. Hannan,
 
3
 
 Brian J. Sutton,
 
2
 
 
 
Hannah J. Gould,
 
2
 
 and James M. McDonnell
 
1
 
1
 
Laboratory of Molecular Biophysics, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, England, UK
 
2
 
Randall Division of Cell and Molecular Biophysics, King’s College London, London SE1 1UL, England, UK
 
3
 
Department of Medicine and 
 
4
 
Department of Immunology, Health Science Center, University of Colorado, Denver, CO 80262
 
The low-affinity immunoglobulin E (IgE) receptor, CD23 (Fc
 

 
RII), binds both IgE and CD21 
and, through these interactions, regulates the synthesis of IgE, the antibody isotype that 
mediates the allergic response. We have determined the three-dimensional structure of the 
C-type lectin domain of CD23 in solution by nuclear magnetic resonance spectroscopy. An 
analysis of concentration-dependent chemical shift perturbations have allowed us to 
identify the residues engaged in self-association to the trimeric state, whereas ligand-
induced changes have defined the binding sites for IgE and CD21. The results further reveal 
that CD23 can bind both ligands simultaneously. Despite the C-type lectin domain structure, 
none of the interactions require calcium. We also find that IgE and CD23 can interact to 
form high molecular mass multimeric complexes. The interactions that we have described 
provide a solution to the paradox that CD23 is involved in both up- and down-regulation of 
IgE and provide a structural basis for the development of inhibitors of allergic disease.
 
IgE binds to its effector cells through either
Fc
 

 
RI, the high-affinity receptor, or CD23
(Fc
 

 
RII), the low-affinity receptor. The former
mediates the IgE effector functions with mast
cells and basophils in type I immediate hyper-
sensitivity. CD23 has multiple functions that
are controlled by a range of different ligands.
These include IgE (both in its secreted form
and on membranes of committed B cells),
CD21 (also known as complement receptor
2), CD18/CD11b and CD18/CD11c (com-
plement receptors 3 and 4, respectively), and
the vitronectin receptor (1). The interactions
with IgE and CD21 are pivotal in IgE regula-
tion (2). Paradoxically, CD23 engages in both
the up- and down-regulation of IgE synthesis,
thereby constituting a two-way switch in IgE
homeostasis (reviewed in reference 1).
CD23 is a 45-kD type II membrane protein
expressed in various cell types, including B
cells. It is unique among Fc receptors in its
homology to C-type (calcium-dependent) lectins
(1) and is also closely homologous, and geneti-
cally linked on human chromosome 19, to
DC-SIGN (3). IgE and CD21 are known to
bind to this lectin domain (4). Two CD23 lectin
domains can bind to the C
 

 
3 domains in IgE
(5). CD21 comprises a tandem array of 15–16
short consensus repeat domains; CD23 binds
to domains 1–2 (D1-2) and domains 5–8 (D5-8)
via protein–protein and protein–carbohydrate
interactions, respectively (6).
The structures of the CD23 ligands, IgE Fc
(7) (as well as the C
 

 
3-4 subfragment [8]), and
the two NH
 
2
 
-terminal short consensus repeat
domains of CD21(D1-2) (9) are known from
X-ray crystallography. In contrast, that of the
CD23 lectin domain has only been inferred
by modelling, based on available sequence
homologies (10). We have used nuclear mag-
netic resonance (NMR) to determine the three-
dimensional structure of the lectin domain and
to locate the residues involved in IgE and
CD21 binding. We have also searched for the
interactions of the lectin domain with calcium
and a set of possible mono/disaccharide ligands
to evaluate its lectin function.
Like DC-SIGN and several other C-type
lectins, CD23 self-associates through its extra-
cellular sequence by the formation of an
 

 
-helical coiled-coil “stalk.” In the membrane
of B cells, CD23 forms trimers with the three
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lectin domains held together at the end of the 15-nm stalk
(11). The stalk is susceptible to proteolytic cleavage (12),
generating fragments with differing trimerization propensities
depending on the length of the residual stalk. The dust mite
protease Der p I cleaves CD23 close to the lectin domain,
and the resulting monomeric CD23 may be a factor in the
high allergenicity of dust mites (13). We have determined
the structure of a recombinant version of the Der p I frag-
ment of CD23 (derCD23) by NMR spectroscopy, as well as
the location of the IgE and CD21 binding sites. For compar-
ison, we also generated a recombinant soluble CD23 frag-
ment containing the entire extracellular sequence (exCD23).
The opposing activities of CD23 in IgE regulation are
thought to be properties of the soluble and membrane forms.
Soluble CD23 enhances IgE synthesis on binding to CD21
(2). When IgE binds to membrane CD23, further IgE syn-
thesis is suppressed; in CD23-deficient mice, the level of cir-
culating IgE is increased by orders of magnitude (14). The
balance between the two forms of CD23 may accordingly be
expected to regulate the level of IgE synthesis.
CD23 fragments are found in the circulation of normal
human subjects. Elevated concentrations of circulating solu-
ble fragments are commonly associated with inflammatory or
lymphoproliferative diseases, such as rheumatoid arthritis,
asthma, and chronic lymphoblastic leukemia, also known as
CLL (15–17). It has been shown that antibodies to CD23 al-
leviate all three conditions, and an anti-CD23 antibody,
IDEC-152, is in clinical trials for asthma (16) and CLL (17).
Structural information on CD23 and its interactions is needed
if the mechanisms of IgE homeostasis are to be understood
and agents for intervening in this process developed.
 
RESULTS
derCD23 interacts with IgE and CD21
 
We have used surface plasmon resonance to characterize the
interaction between derCD23 and the two protein ligands,
IgE and CD21, involved in IgE regulation, determining
equilibrium and rate constants for the Fc fragment of IgE
(domains C
 

 
2-4) and the D1-2 fragment of human CD21.
For the interaction between C
 

 
2-4 and derCD23, we
observed a marked change in affinity and off rates depending
on the immobilization density of derCD23. At low density,
C
 

 
2-4 and CD21(D1-2) both show fast-on/-off kinetics
with a resulting K
 
D
 
 
 

 
 1.3 
 

 
 0.3 and 0.87 
 

 
 0.09 
 

 
 10
 

 
6
 
 M,
respectively (Fig. 1, A and B). At a higher immobilization
density of derCD23 the rates of dissociation of C
 

 
2-4 are
markedly reduced (Fig. 1 D). C
 

 
2-4 is a dimer, and the pres-
ence of two copies of the C
 

 
3 domain may therefore explain
this effect; the dimer has the potential to make a bivalent in-
teraction and the observed affinity differences are then
caused by cooperative binding. The monovalent CD21(D1-2)
construct showed no change in apparent affinity at higher
derCD23 densities (Fig. 1 C).
When C
 

 
2-4 is the immobilized component, binding of
derCD23 (Fig. 1 E), which is monomeric under these con-
ditions as shown by sedimentation equilibrium (molecular
mass 
 

 
 18,086 
 

 
 350 dalton [D]; unpublished data), gives
similar values to C
 

 
2-4/derCD23 (Fig. 1 B). In contrast, the
binding of exCD23, with the complete extracellular se-
quence, shows a considerably higher affinity, with a mark-
edly slower off rate (Fig. 1 F). In fact, these binding curves of
exCD23 with C
 

 
2-4 show two components with different
affinities (K
 
D
 
 
 

 
 1.1 
 

 
0.2 
 

 
 10
 

 
6
 
 M and 3.9 
 

 
 0.6 
 

 
 10
 

 
8
 
 M)
and interaction kinetics. This effect is clearly reflected in
the dissociation kinetics (Fig. 1 F; one minor component
with a rate constant of 4 
 

 
 10
 

 
2
 
 s
 

 
1
 
 and a major component
with an off-rate constant of 5 
 

 
 10
 

 
4
 
 s
 

 
1
 
). Because exCD23
is also monomeric in solution under these conditions, as de-
Figure 1. Surface plasmon resonance analysis of CD23 interactions 
with CD21 and IgE. The binding of CD21(D1-2) (A and C) and IgE C2-4 
(B and D) to immobilized derCD23 was determined over a range of ligand 
concentrations: 62.5 (black), 125 (red), 250 (green), 500 (cyan), 1,000 
(blue), and 2,000 nM (purple). Binding to CD23 was tested at a low ligand 
density (LD; panels A and B) and at a high ligand density (HD; panels C and 
D). The reverse orientation, binding derCD23 and exCD23 to immobilized 
C2-4 (E and F), was also characterized for the same concentration range. 
Representative sensorgrams are shown here. The KD value for the mono-
meric interactions between derCD23 and CD21(D1-2) (A and C) is 8.7  
0.9  107 M and for derCD23 to C2-4 (B and E) is 1.3  0.3  106 M. 
The interaction between exCD23 and C2-4 (F) shows a distinct biphasicity, 
with two binding constants of 1.1  0.2  106 and 3.9  0.6  108 M. 
The interaction between C2-4 and the high-density derCD23 surface (D) 
show complex kinetics that indicate several distinct binding events. It is 
markedly different from the interaction with the low density derCD23 
surface (B), showing much slower dissociation rates.
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termined by sedimentation equilibrium (molecular mass 
 

 
30,426 
 

 
 908 D; unpublished data), this biphasicity must be
caused by formation of dimers or trimers by enhanced self-
association of lectin domains as they bind to IgE Fc. Thus,
binding of soluble CD23 to IgE Fc promotes oligomeriza-
tion, provided that there is sufficient stalk, as in exCD23. A
weak interaction between CD23 lectin domains is also evi-
dent from our NMR studies of derCD23 at elevated con-
centrations (see derCD23 oligomerization). Upon oligomer-
ization of CD23 in the complex with IgE Fc, it will gain the
capacity to bind additional IgE Fc molecules. Indeed, the
sedimentation equilibrium profile indicates the formation of
a heterogeneous mixture of high molecular mass complexes,
which cannot be modeled to determine its size distribution
(unpublished data).
The analogy with other members of the C-type lectin
superfamily would suggest that the structure and activity of
CD23 might be dependent on calcium, and there is some
experimental evidence in favor of this inference (18, 19).
We performed binding experiments in the presence of
10 mM EDTA after stripping derCD23 of calcium by over-
night incubation in EDTA. The binding of IgE Fc showed a
small (sevenfold) decrease in affinity (to a K
 
D
 
 of 9.1 
 
 
 
0.9 
 

 
10
 

 
6
 
 M) due almost entirely to a change in on rate (unpub-
lished data). This is consistent with the expectation that the
calcium affects the conformation of certain loops, based on
observations of other C-type lectins, but calcium is not in-
volved directly in binding. The affinity of the CD21(D1-2)
interaction was unaffected by the removal of calcium.
 
The structure of CD23
 
The three-dimensional structure of derCD23 was solved by
heteronuclear NMR spectroscopy, and its interactions with
its ligands were examined. Assignment of backbone and
side-chain resonances were performed by CBCA- and nu-
clear overhauser effect (NOE)–based assignment strategies;
trosy-based pulse sequences were used to improve the effi-
ciency of the triple resonance experiments (20). Additional
data were collected to characterize derCD23 dynamics and
hydrodynamics. Analysis of dynamics from 
 
15
 
N relaxation
gives a direct measure of backbone flexibility. The derCD23
lectin domain is generally structurally rigid, with highly flex-
ible NH
 
2
 
 and COOH termini and three internal loops (
 

 
2-
 

 
4, 
 

 
4-
 

 
5, and 
 

 
5-
 

 
6) showing some degree of flexibility.
Five amino acids from a central loop (
 

 
5-
 

 
6) could not be
assigned; residues flanking this loop show increased trans-
verse relaxation rates, suggesting that this region experiences
motions on the ms-
 

 
s time scale and that loss of peaks is
probably caused by line broadening (NMR relaxation data
are shown in Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20050811/DC1).
The structure of derCD23 was based on 
 
	
 
2,300 NMR-
derived structural constraints, including 
 
	
 
2,100 structurally
relevant NOEs, 96 dihedral angle constraints from the pro-
gram TALOS (see Materials and methods) (21), and 30 hy-
drogen bonds, implied by hydrogen–deuterium exchange
experiments and local secondary structure. A summary of re-
straints used is shown in Table I. The average density of
structural constraints was 
 

 
25 per residue over the second-
ary structure elements of the protein.
The three-dimensional structure of derCD23 consists of
two roughly orthogonal 
 

 
 helices and eight 
 

 
 strands form-
ing two antiparallel 
 

 
 sheets. Four disulphide bonds contrib-
ute to the tertiary structure, whereas seven tryptophan resi-
dues and other conserved side chains form a hydrophobic
core within the domain. The topology is that of a C-type
lectin domain. It shows the greatest sequence and structural
homology to the lectin domains of DC-SIGN, the H1 sub-
unit of the asialoglycoprotein receptor, and human lung sur-
factant protein D, with sequence identities of 36, 35, and
26%, respectively, and root mean squared (r.m.s.) deviations
of 2.7–2.8 Å over 118–126 residues. The global r.m.s. devia-
tion for the NMR-derived ensemble of 20 structures is 0.26
Å for backbone atoms and 0.8 Å for heavy atoms in all ele-
ments of secondary structure. A bundle of the 20 lowest en-
ergy conformers and a ribbon diagram of the derCD23 struc-
ture are shown in Fig. 2, A and B, respectively. derCD23
shows a marked polarity in its electrostatic character. The
 
Table I.
 
Summary of restraints and structural statistics
 
a
 
Component Quantity
 
Restraints
NOEs
Intraresidue 973
Sequential 421
Medium range (i 
 


 
 5) 213
Long range 572
Total NOEs 2179
Dihedral Angles (
 
 
 
and 
 

 
) 96
Hydrogen bonds 30
Total number of restraints 2335
Number of violations
Distance restraints (
 
	
 
0.3 Å) 0
Dihedral angle restraints (
 
	
 
5
 

 
) 0
Precision
 
b,c
 
Backbone heavy atoms (Å) 0.267
All heavy atoms (Å) 0.854
Structure quality
Residues in most favored regions 65.4%
Residues in additionally allowed regions 27.7%
Residues in generously allowed regions 5.2%
Residues in disallowed regions 1.7%
 
a
 
The three-dimensional coordinate file for the protein is available from the Protein 
Data Bank under accession no. 1T8D.
 
b
 
Values reported are the average values greater than the 20 lowest energy structures.
 
c
 
The average r.m.s. deviation for the coordinates set was calculated by superimposing 
each of the 20 structures onto the lowest energy structure. The superposition was 
over backbone and heavy atoms of residues 166–169, 172–178, 183–193,196–198, 
204–213, 217–225, 230–234, 158–162, 266–271, and 278–285.
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surface is highly charged, but the positive and negative
charges are found on opposite faces (Fig. 2 C). The highly
charged character will affect how CD23 interacts with ligands
and appears to be particularly important in self-association.
We observed two distinct conformations for the der-
CD23 protein (conformations A and B, available from
the Protein Data Bank under accession nos. 1T8D and
1T8C, respectively) in an area around the hydrophobic face
of 
 
-helix 1. Twenty residues show two sets of peaks in 1H-
15N–HSQC spectra. Based on relative peak intensities, the
two conformations are roughly equally populated. The rela-
tive occupancies of the conformations did not change under
a large number of conditions tested, including changes in
concentration, temperature, pH, and ionic strength and in
several ligand-binding experiments. The two conformations
are in slow exchange on the NMR timescale. Each con-
former gave rise to a distinct set of NOEs; based on 220 dis-
tinct NOEs, independent ensembles of structures were cal-
culated for each conformation. The two conformations
differ in the extent of hydrophobic packing between the first
 sheet (1, 2, 3, and 8) and -helix 1. This results in
small changes in overall structure but marked changes in
chemical shift for nearby residues because of the change of
orientation of three aromatic side chains (Y176, W167, and
W280) in this region. Because the biological importance of
these two conformers is not clear at present, we will not
dwell on them further here, and they will be described in
detail elsewhere (unpublished data).
The CD23 calcium binding site and the lectin 
functions of CD23
X-ray crystallography of related C-type lectin-like domains
(CTLDs) has shown one to three calcium binding sites per
domain (22), but the calcium and carbohydrate binding
properties of CD23 have been difficult to predict. Ca2 site
2 in derCD23 is reasonably well conserved, but the canoni-
cal Ca2 site 1 is poorly conserved (23). In other CTLDs,
site 2 is directly involved in binding carbohydrates.
We studied the calcium-binding behavior of derCD23 by
monitoring the effects of calcium titration on the 1H-15N–
HSQC spectrum. derCD23 was expressed and refolded in
the presence of 25 mM EDTA, and the EDTA was removed
by dialysis. The calcium-free sample was well folded with
only very few residues showing substantial chemical shift
changes from the calcium-bound sample, in contrast to some
other CTLDs that require Ca2 for proper folding (24).
Eleven datasets were collected with Ca2 concentrations
ranging from 100 M to 50 mM. Over the course of this ti-
tration, seven residues showed large proton chemical shift
changes (	0.08 parts per million [ppm]): backbone amides
for I221, N225, K229, G230, E231, D270, A271, and D274
and the side-chain amide resonances of N225. Saturation
binding curves for each of the eight sites were measured, and
all were in good agreement, giving a KD of 1.80  0.15 mM
(Fig. 3, inset). Surprisingly, the observed pattern of chemical
shift changes suggests occupancy of Ca2 site 1, but presents
no evidence for the occupancy of Ca2 site 2 (Fig. 3).
We also tested the ability of derCD23 to interact with a
series of carbohydrate ligands. Individual NMR chemical
shift perturbation titrations were performed with galactose,
glucose, lactose, mannose, and N-acetylglucosamine to a fi-
Figure 2. The structure of derCD23. (A) View of the backbone (N, C, 
C) of 20 superimposed NMR-derived structures of derCD23. (B) A ribbon 
diagram of the lowest energy conformer of derCD23, with secondary 
structural elements identified. (C) A surface representation of derCD23 
colored according to electrostatic potential and coded such that regions 
with a potential 
4 kBT are red, whereas those 	4 kBT are blue. kB, 
Boltzmann constant; T, absolute temperature.
Figure 3. The calcium binding site on CD23. The backbone cartoon of 
CD23 is shown in gray and the canonical CTLD calcium ions are indicated 
with blue spheres. Conserved potential chelating atoms are indicated and 
are colored red for site 1 and blue for site 2. Residues that show large 
changes in chemical shift (HN  0.08 ppm) on the addition of calcium 
are mapped onto the protein surface and are indicated in yellow. The inset 
shows the binding isotherm based on change in chemical shift position; 
results and standard deviations (KD of 1.80  0.15 mM) are from the 
seven residues that show proton chemical shift changes of 0.08 ppm. 
These results suggest the occupancy of Ca2 site 1 only.
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nal carbohydrate concentration of 125 mM. Even at the
highest concentrations, none of these compounds bound to
derCD23. In conjunction with the apparent absence of Ca2
site 2, CD23, if it binds sugars at all, must do so using a dif-
ferent mode from the canonical CTLD carbohydrate recog-
nition mechanism.
The interaction surface of derCD23 for IgE
To investigate the nature of the CD23’s interaction with IgE,
the Fc fragment of IgE (C2-4) was titrated with 15N-labeled
derCD23. During the titration, most of the peaks in the
trosy-HSQC spectrum disappeared because of line broaden-
ing. Only peaks mapping to the COOH terminus of the
derCD23 fragment remained visible (unpublished data); the
relaxation analysis indicated that these residues have motion
independent from the overall tumbling characteristics of the
protein. These observations are consistent with the formation
of a high-order oligomer of the C2-4–derCD23 complex.
To map the ligand binding surfaces of CD23 with IgE,
we instead titrated a monomeric C3 domain against a 15N-
labeled derCD23 sample (Fig. 4 A). It has been reported that
the entire CD23 binding site is contained within the C3
domain (25). Residues W184, R188, Y189, A190, L198,
H202, I221, G222, R224, N225, L226, W234, V235, A271,
C273, D274, K276, and A279 in derCD23 exhibited con-
siderable concentration-dependent changes in chemical shifts
and line broadening on addition of C3. The residues, when
mapped onto the derCD23 surface, reveal a continuous in-
teraction surface for C3 on the CD23 lectin domain (Fig. 4
C). The complete list of chemical shift changes observed
during the C3 titration are available in the BioMagRes-
Bank database under accession no. 6734.
The interaction surface of derCD23 for CD21
We identified the interaction surface of CD21 on CD23 by ti-
trating unlabeled CD21(D1-2) against 15N-labeled derCD23
(Fig. 4 B). This CD21 construct is identical to the one cocrys-
tallized with C3d (9). Four residues of derCD23 show chemi-
cal shift perturbations, all of which are in the COOH-terminal
“tail” (residues E294, G295, S296, and E298; Fig. 4 C). Resi-
due S293 was not assigned, whereas the peak for residue A297
lies in a region of considerable overlap in the 15N-HSQC,
making it difficult to identify its position unambiguously. Res-
idue A292 does not show a change in chemical shift, and,
hence, we infer that the CD21 interaction site comprises the
COOH-terminal six residues of this CD23 construct. We
note that the full-length CD23 COOH-terminal tail, with an
additional 23 residues, may have a higher affinity for CD21
than the derCD23 fragment. Further studies will focus on this
and the binding to other domains of CD21 (6).
Despite a high degree of conservation between the lectin
head region of human and mouse CD23 (62% over 143 resi-
dues), the COOH-terminal region of derCD23 is not con-
served between species (2 identities over the 10 COOH-ter-
Figure 4. 1H-15N chemical shift perturbation experiments define the 
interaction surfaces on derCD23 for C3 and CD21(D1-2). A small 
number of residues show chemical shift perturbation on addition of IgE C3 
or CD21(D1-2). Example spectra illustrating this are shown in (A) and (B), 
respectively. Insets show expanded views of the indicated areas. (C) Residues 
that show substantial chemical shift changes are mapped onto the derCD23 
surface and are colored green for C3 and blue for CD21(D1-2). The orien-
tation of this molecule is identical to that shown in Fig. 2.
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minal residues). Thus, the location of the CD21 binding site
suggests that this interaction may not occur in the mouse, in
agreement with binding studies (Conrad, D.H., personal com-
munication). This helps to explain important differences in IgE
regulation between human and murine systems (see below).
The CD23–IgE–CD21 trimolecular complex
The two NMR titration experiments identify independent
binding sites for CD21(D1-2) and IgE on CD23. We con-
firmed the independent nature of the interactions by forming
the trimolecular complex (derCD23–C3–CD21(D1-2))
through sequential titrations showing additivity of the effects
on the spectrum of the separate interactions (unpublished data).
derCD23 oligomerization
At a concentration of 100 M, derCD23 has an apparent
molecular mass of 16.5 kD, but at 1.2 mM of derCD23 a
monomer–oligomer equilibrium supervened, with a mass-
average molecular mass of 28 kD, with both values esti-
mated from NMR-based translational diffusion measure-
ments (26). This self-association is accompanied by a change
in the chemical shifts of some of the peaks in the HSQC
spectrum. These residues (L198, K212, H213, N225, E231,
V240, and Y242) map to the two distinct regions with op-
posite charge characteristics and suggest a possible self-associ-
ation interaction surface.
On the basis of this postulated interaction surface, we
generated a model for the trimer formed by full-length
CD23 (Fig. 5). X-ray structures of other C-type lectin trim-
ers have been determined, and the arrangement of the sub-
units are all similar in mannose-binding protein (MBP), pul-
monary surfactant apoproteins D and A, and tetranectin (23).
The NMR data predict a different arrangement for the
CD23 trimer. MBP, pulmonary surfactant apoproteins D
and A, and tetranectin all possess a similar nucleating heptad
repeat sequence at the top of the coiled-coil stalk that allows
the formation of a largely hydrophobic interface. Although
CD23 has strong homology to these proteins in the lectin-
like domain, it differs in this interface motif. Furthermore,
an MBP-type arrangement for CD23 would result in an
electrostatically repulsive interface. The interface predicted
from the NMR chemical shifts presents an electrostatically
favorable interface and results in completely solvent-exposed
interaction sites for IgE and CD21 (Fig. 5).
DISCUSSION
The structure of derCD23 and its complexes with 
IgE and CD21
The NMR structure of derCD23 confirms that it has the to-
pology of a C-type lectin domain, as predicted by sequence
homology to other members of this family. NMR spectra
revealed an equilibrium between two structures that differ in
the hydrophobic packing between two of the structural ele-
ments. Structural plasticity has been suggested to confer an
advantage in allowing greater diversity of ligand recognition
(27). CD23’s conformational heterogeneity could potentially
play a role in its interactions with ligands. However, IgE,
CD21, or calcium binding do not affect the relative propor-
tions of the two conformers, which leads us to conclude that
both conformers bind to these ligands equally well. Surpris-
ingly, occupation of only one of the putative calcium-bind-
ing sites (Ca2 site 1) could be confirmed. Because Ca2 site
2 is involved in carbohydrate recognition by other CTLDs,
this result is in accord with the observation that glycosylation
is not required for the binding to either IgE (28) or
CD21(D1-2) (6). The results also demonstrate that calcium
is not required to stabilize the configuration of CD23 for
binding these ligands.
We have observed cooperativity and biphasicity in the
binding of C2-4 to derCD23 (Fig. 1 D) and of exCD23 to
C2-4 (Fig. 1 F). The latter corresponds well with the re-
ported biphasic kinetics of IgE binding to monomers and tri-
mers of membrane CD23 at the cell surface (11, 29). At the
concentrations of the Biacore experiments (see Materials and
methods), we know from sedimentation equilibrium that
both derCD23 and exCD23 are entirely monomeric, and,
thus, the IgE Fc must stabilize their oligomerization, more so
for exCD23 because it contains the stalk as well as the lectin
domain. Ligand-induced oligomerization of exCD23 may
be a further example of coupled folding and protein binding
(30). In contrast to the interaction with IgE, there was no
concentration dependence or evidence of cooperativity in
the binding of CD21(D1-2) to derCD23 (Fig. 1, A and C),
suggesting that a single lectin domain of CD23 (with a com-
Figure 5. The CD23 trimer and the architecture of ligand interaction 
sites. (A) An overhead view of the postulated CD23 trimer is shown. For 
each monomer, a backbone ribbon cartoon is shown in gray, and residues 
that show concentration-dependent chemical shift changes are displayed 
in a surface representation. The surfaces are colored according to electro-
static charge, demonstrating the electrostatic complementarity of the two 
sites. Side chains for residues that are part of the IgE interaction site are 
displayed and colored in green. (B) Cartoon representations (top and side 
views) illustrating the overall architecture of the trimer and the ligand 
binding sites. The two oligomerization sites are colored blue and red, 
respectively, the IgE interaction site is green, the CD21 binding site is cyan, 
and the calcium binding site is yellow. The front two molecules of the 
trimer are semitransparent.
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plete tail region) contains the complete binding site for this
region of CD21.
In addition to showing that the binding sites on CD23
for IgE and CD21 are distinct from each other (Fig. 4 C) and
from the trimerization interface (Fig. 5), we also found that
derCD23 can bind both ligands simultaneously to form a tri-
molecular complex. We observed the formation of high mo-
lecular mass complexes between C2-4 and derCD23 by
NMR and have seen a similar result with C2-4 and
exCD23 by sedimentation equilibrium (unpublished data).
These properties help us to understand the functions of
CD23, and, in particular, they support a proposed mecha-
nism of IgE homeostasis, illustrated in Fig. 6 and discussed in
detail below.
Up-regulation of IgE synthesis
Soluble CD23 is implicated in the up-regulation of IgE syn-
thesis: its attachment to CD21 on peripheral blood B cells
before differentiation into IgE-secreting plasma cells en-
hances IgE synthesis (2). A mechanism for the up-regulation
of IgE synthesis was originally suggested by analogy to the
process of up-regulation of antibody synthesis in the im-
mune response by C3d fragments of complement compo-
nent C3. C3d fragments, covalently linked to the antigen,
coligate antigen receptor (IgM) and CD21 on naive B cells
(31, 32), leading to cell proliferation and antibody synthesis.
We have founds that B cells express membrane IgE and
CD21 before differentiation into the IgE-secreting plasma
cells (unpublished data). Thus, soluble CD23 may up-regulate
IgE synthesis by coligation of membrane IgE and CD21 on
these transitional cells, resulting in selective proliferation and,
ultimately, higher levels of IgE synthesis (Fig. 6, right). Such a
mechanism is supported by our observation that coligation of
membrane IgM and CD21 by anti-IgM (acting as a surrogate
antigen) and CD23 stimulates B cell proliferation (33). Our
discoveries that the binding sites for IgE and CD21 are dis-
tinct and that both ligands can bind simultaneously support
the co-cross-linking of membrane IgE and CD21 by soluble
CD23. If correct, then the inhibition of membrane CD23
cleavage or soluble CD23 binding to either IgE or CD21 of-
fers potential targets for therapy, and the data presented here
will provide a structural basis for designing inhibitors.
Feedback regulation of IgE synthesis
Membrane CD23 is associated with the down-regulation of
IgE synthesis (Fig. 6, left). CD23-deficient mice exhibit
abnormally high serum IgE levels, whereas CD23-overex-
pressing mice show decreased IgE synthesis and reduced sus-
ceptibility to systemic anaphylaxis (34). Cross-linking of
membrane CD23 on human B cells by IgE or IgE–antigen
complexes or by anti-CD23 antibodies inhibits B cell prolif-
eration and IgE production (35, 36). An anti-CD23 mono-
clonal antibody has accordingly shown promise for lowering
serum IgE levels in clinical trials (16). Moreover, co-cross-
linking of CD23 with surface immunoglobulin induces the
apoptosis of B cells (37), and, thus, antigen–IgE complexes
may regulate the population of the specific IgE antibody–
producing B cells.
Our study sheds light on possible mechanisms of feed-
back regulation of IgE by membrane CD23. The binding of
IgE to membrane CD23 prevents cleavage and release of the
soluble CD23 fragments that stimulate IgE synthesis. Our
finding that IgE Fc cooperatively binds two lectin domains
of CD23 and appears to promote oligomerization of
exCD23 explains how IgE might stabilize the trimer of
membrane CD23 on the cell surface, rendering it less sus-
ceptible to proteolysis. The observation of high molecular
mass complex formation between IgE Fc and derCD23 indi-
cates how exogenous IgE could be endocytosed and de-
graded. Furthermore, the co-cross-linking of membrane
CD23 and specific antibodies by IgE–antigen complexes
may steal the endogenous membrane IgE from CD21, thus
antagonizing the positive feedback pathway (Fig. 6).
Pivotal role of CD23 in IgE homeostasis
The main effector function of IgE is thought to be sensitiza-
tion of mast cells for allergen triggering of an allergic re-
sponse. This serves as protection against parasite infections,
but confers the risk of allergic disease in susceptible individu-
als. The lower affinity of IgE for CD23 (KD  107–
108 M) than for FcRI (KD  1010–1011 M), collec-
tively with feedback regulation of IgE synthesis by IgE, en-
sures that the mast cells remain sensitized once excess IgE has
been removed. According to the scheme in Fig. 6, soluble
CD23, released by B cells on stimulation in the immune re-
sponse, would initially up-regulate IgE synthesis by coligat-
ing membrane IgE and CD21. As IgE concentrations enter
the range in which binding to membrane CD23 becomes
important, IgE synthesis would be abruptly terminated. This
would preclude the accumulation of dangerous levels of IgE.
The isotype specificity of this mechanism is explained by the
fact the switch between up- and down-regulation pivots
around IgE itself (Fig. 6). The structure of CD23 and the tri-
mer model, the location of its binding sites for IgE and
Figure 6. Competition between CD23 and CD21 for membrane IgE 
on the B cell surface. (left) Co-cross-linking of membrane CD23 and 
membrane IgE by an allergen–IgE complex leads to down-regulation of IgE 
synthesis. (right) Trimeric soluble CD23 co-cross-linking of membrane IgE 
and CD21 leads to up-regulation. IgE binding to membrane CD23 also protects 
the latter against proteolysis and prevents formation of soluble CD23.
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CD21, and the clustering of CD23 caused by IgE Fc lend
support to this mechanism and suggest strategies for down-
regulation of IgE levels to treat allergic disease.
MATERIALS AND METHODS
Protein expression and purification. derCD23 (P06734) comprises the
amino acids Ser156 to Glu298. The human derCD23 construct was subcloned
from CD23 cDNA (38) by PCR. Recombinant derCD23 was expressed in
the Escherichia coli host strain BL21(DE3), extracted from the cell pellets, and
refolded by Taylor’s procedure (39). Unlabeled and 15N- and 13C-labeled
derCD23 were prepared on minimal media or with the addition of [13C]glu-
cose/[15N]H4Cl to the media. Proteins were purified by hydrophobic interac-
tion chromatography on a phenyl sepharose column (GE Healthcare). Mass
spectrometry of these materials was performed on a mass spectrometer (Micro-
mass Platform-II ESI; Waters). Reverse-phase HPLC-purified unlabeled, 15N-
labeled, and 13C, 15N–labeled material had masses of 16,143  4, 16,334  3,
and 16,995  5 D, respectively, confirming the identity of the material and in-
dicating that isotope incorporation was highly efficient. ExCD23, comprising
Asp48 to Ser321, was subcloned from CD23 cDNA, expressed in E. coli, ex-
tracted, and refolded as described above for derCD23. Recombinant human
CD21(D1-2), C2-4 (provided by A. Beavil, Kings College London, London,
UK), and C3 (provided by N. Price, University of Oxford, Oxford, UK)
constructs were prepared as described previously (9, 11, 40, 41).
Surface plasmon resonance. All experiments were performed at 25C
on an automated instrument (Biacore 2000; Biacore AB). A specific binding
surface was prepared by coupling derCD23 to a CM5 sensor chip through
the amine coupling procedure. Coupling densities of 3,000 (high density)
and 400 resonance units (low density) were used. C2-4 and CD21(D1-2)
in HBS (10 mM Hepes, pH 7.4, 150 mM NaCl, 4 mM CaCl2, and 0.005%
[vol/vol] surfactant p20) were injected over the sensor chip at 10 l min1
with a 3-min association phase followed by a 15-min dissociation phase.
Binding was also tested at higher flow rates and showed no change in inter-
action characteristics. In the reverse binding experiment, a biotinylated
C2-4 protein was immobilized at low density on a streptavidin chip, and
soluble derCD23 or exCD23 was injected over the surface. Biotinylation of
C2-4 was performed by mixing C2-4 with 6-(biotinamidocaproylamido)
caproic acid succinamide ester (Sigma-Aldrich) at a ratio of 3:1, a process
that generally ensures a single biotinylation site per protein, followed by gel
filtration. When necessary, regeneration of the sensor surface was performed
using three 60-s pulses of 0.2 M glycine-HCl, pH 2.5. Injections over un-
derivatized sensor surfaces were performed to test for nonspecific binding.
The IgE, CD23, and CD21 proteins were well behaved in the Biacore ex-
periments, with essentially no nonspecific binding to control flow cells, effi-
cient regeneration of sensor surfaces, and excellent reproducibility. Standard
double referencing data subtraction methods (42) were used before analysis
of rates and equilibrium binding. Curve fitting and other data analyses were
performed using MicroCal Origin 6.1 (OriginLab Corporation).
NMR spectroscopy. NMR samples were prepared from concentrated
derCD23 dialysed into a buffer containing 25 mM Tris, 125 mM NaCl, and
4 mM CaCl2, pH 6.8, and placed in a Shigemi NMR tube (Shigemi Corp.).
All NMR data were collected at 35C on home-built spectrometers operat-
ing at proton frequencies of 500, 600, and 750 MHz (Omega/GE Health-
care). The assignment and structure determination of derCD23 were per-
formed using standard heteronuclear NMR experiments as described in
McDonnell et al. (43). Assignments made use of the following NMR ex-
periments: HNCA, HN(CO)CA, HNCACB, HN(CO)CACB, HNCO,
HN(CA)CO, 15N–TOCSY–HSQC (mixing times of 16 and 25 ms), and
HCCH-TOCSY (mixing time of 11 ms). All triple resonance experiments
were collected using trosy-based sequences (20). Three residues in the NH2
or COOH termini (residues 156–157 and 293) and five residues (residues
252–256) in a central loop were not assigned, as well as five other residues
in loops and turns (residues 181, 215–216, 249, 263). Several approaches
were used to try to help in the assignment of these residues, including
changes in temperature, concentration, pH, ionic strength, and CaCl2 con-
centration, without success. NOE correlations were measured using 15N-
and 13C-edited 3D-NOESY experiments and a 2D-NOESY in D2O (all
mixing times of 125 ms). The backbone torsion angles  and  were de-
rived for the well-defined secondary structure elements using TALOS (21).
Structure calculations were performed using the program CNS (version 1.1)
(44) in an ab initio–simulated annealing protocol with a two-stage torsion
angle dynamics and a Cartesian dynamics protocol. From 100 calculations,
the 20 structures with the lowest energies were selected and subjected to a
four-step refinement stage, adjusting for uncertainties in NOE restraints
length because of overlap or spectral artifacts. Statistics for the resulting fam-
ily of structures are listed in Table I.
Backbone 15N relaxation parameters, measuring the rates of 15N longitu-
dinal (R1) and transverse (R2) relaxation and the 1H-15N steady-state NOE,
were collected using previously described methods (45). The “model-free”
characteristics of the local motions (46) were derived from these parameters
using the program DYNAMICS, and hydrodynamic characteristics were cal-
culated using the program ROTDIF (47). Fitting the relaxation rate for all
structured residues (S2 	 0.8), the following values for overall rotation were
calculated: c  9.32  0.22 ns and D||/D⊥  1.40  0.06.
For chemical shift perturbation experiments, unlabeled ligands were ti-
trated in small aliquots to samples of 15N-labeled derCD23. Chemical shift
changes () in 1H-15N–HSQC spectra were followed until saturation, typ-
ically collecting 6–8 spectra per titration. Where possible, ligand samples
were lyophilized and added as a powder to minimize volume changes dur-
ing the experiment. For the calcium titration, the dissociation constant (KD)
was estimated from the titration curves of all residues that showed consider-
able chemical shift changes by plotting the relative magnitude of  as a
function of calcium concentration. A complete table of chemical shifts for
derCD23 at low and high concentrations, chemical shifts for derCD23
bound to CD21, and the chemical shifts during the IgE C3 and calcium ti-
trations are available from the BioMagResBank database under accession
nos. 6732, 6733, 6734, and 6735.
Fast-exchanging amide protons were determined using a two-dimen-
sional heteronuclear water exchange filter sequence (WEX II-FHSQC) (48).
Mixing times of 100 and 500 ms for the water magnetization transfer were
set. In the analysis of these data the intensities of the observed peaks were
normalized against a native HSQC and plotted against residue number.
Measurements of translational diffusion coefficients were performed us-
ing pulsed field gradient methods. 16 1-D spectra, with gradient strengths
varying from 6.5 to 65 G cm1, were acquired. Intensities of NMR signals
were fitted to standard equations to derive diffusion coefficients (26).
Online supplemental material. Fig. S1 shows a summary of the derCD23
secondary structure and dynamics analysis. Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20050811/DC1.
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